Full CoverageAll coverage
The week in pharma: action, reaction and insight – week to July 4
By Barbara Obstoj-cardwell
Penn spinoff Capstan has been acquired by AbbVie for $2.1B to fight autoimmune disease by reengineering cells inside the body
By Sarah Gantz & Kayla Yup
In Vivo CAR-T Interest Grows With AbbVie Acquisition
By Andrew McConaghie
Friday Five – Capstan deal fuels AbbVie's CAR-T drive, Sage burns out, regulatory rollercoaster rages on...and more
By Jessica D'Amico
Cooley Advises Capstan In Sale To AbbVie Worth Up To $2.1B
By Rae Ann Varona
AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
By Frank Vinluan
AbbVie to buy Capstan for up to $2.1 billion in immunology push
By Christy Santhosh
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
By Dan Samorodnitsky
AbbVie to expand RNA capabilities with $2.1bn acquisition of Capstan Therapeutics
By Swagath Bandhakavi
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
By Robert Barrie
AbbVie Buying Capstan Therapeutics In $2.1 Billion Deal
By Amit Chowdhry
Abbvie confirms $2.1B Capstan swoop
By Ian Lyall & Emily Jarvie
AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition
By Alaric DeArment
AbbVie to buy Capstan for up to $2.1 billion in immunology push
By Christy Santhosh & Sriraj Kalluvila